What is Crizotinib?

Crizotinib is a targeted therapy categorized as a selective tyrosine kinase inhibitor (TKI). It is a first-in-class precision medicine used for treating specific types of non-small cell lung cancer (NSCLC) and certain rare soft-tissue tumors. By targeting and blocking the specific abnormal proteins that drive cancer cell growth, it disrupts the survival signals of tumor cells, slowing down disease progression and offering a highly effective alternative to traditional cytotoxic chemotherapy.

What is Crizotinib Used For?

Crizotinib is indicated for adults and, in specialized cases, pediatric patients diagnosed with tumors driven by specific genetic alterations. It is widely used in several clinical settings, including:

• ALK-Positive Non-Small Cell Lung Cancer (NSCLC): Used as a highly effective first-line or subsequent therapy for patients whose tumors test positive for an abnormal anaplastic lymphoma kinase (ALK) gene.
• ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Approved as a primary targeted treatment option for patients with advanced NSCLC harboring a ROS1 gene mutation.
• Anaplastic Large Cell Lymphoma (ALCL): Indicated for pediatric patients (age 1 and older) and young adults with relapsed or refractory systemic ALK-positive ALCL.
• Inflammatory Myofibroblastic Tumor (IMT): Approved for adult and pediatric patients (age 1 and older) with unresectable, recurrent, or refractory ALK-positive IMT, a rare type of soft-tissue tumor.

How Does Crizotinib Work?

In cancers driven by ALK or ROS1 gene rearrangements, the resulting abnormal fusion proteins are constantly active. These mutated proteins act like a broken "on" switch, sending continuous signals that instruct cancer cells to multiply, survive, and spread rapidly.

Crizotinib works by specifically binding to and inhibiting these abnormal kinases. This action:

• Blocks Growth Signaling: It shuts down the downstream chemical pathways required for malignant cells to grow and proliferate.
• Induces Apoptosis: By cutting off crucial survival signals, it triggers programmed cell death (apoptosis) in the cancer cells.
• Targets Precisely: Unlike conventional chemotherapy that destroys all rapidly dividing cells indiscriminately, Crizotinib specifically isolates the mutated ATP-binding sites of ALK and ROS1, sparing more healthy cells.

Benefits of Crizotinib

Clinical applications and landmark trials have demonstrated substantial advantages for patients on Crizotinib:

• Rapid and Robust Efficacy: Significantly shrinks tumors and extends progression-free survival (PFS) in patients with ALK- or ROS1-positive malignancies compared to standard chemotherapy.
• Convenient Oral Dosing: Administered twice daily in capsule form, allowing patients to manage their oncology treatment at home without frequent, lengthy hospital infusions.
• Favorable Tolerability Profile: Provides a highly effective targeted approach, completely avoiding many classic, severe side effects of traditional cytotoxic chemotherapy.

Available Strengths

Crizotinib is commonly available in the following oral capsule strengths to accommodate various patient weights, indications, and clinical dose reductions:

• 200 mg capsules
• 250 mg capsules

Recommended Dosage & Administration

Unlike cyclical chemotherapy treatments, Crizotinib is taken continuously every day without a planned "off-treatment" week, until the disease progresses or unacceptable toxicity occurs.

• Standard Adult Daily Dosage: 250 mg taken orally twice daily (totaling 500 mg per day).
• Pediatric Dosage: Based on body surface area (mg/m2) as determined by the oncologist.

Administration Rules: Crizotinib should be taken at approximately the same times each day (e.g., morning and evening). Swallow the capsules whole with a glass of water. Do not open, crush, or chew them. It can be taken with or without food.

Missed Dose

If a dose of Crizotinib is missed:

• Take it as soon as possible if remembered, provided the next scheduled dose is more than 6 hours away.
• Skip the missed dose entirely if the next dose is due within 6 hours. Do not take a double dose to make up for a missed one.
• If vomiting occurs after taking the drug, do not take an additional dose. Simply take the next scheduled dose at your regular time the following day.

Common & Serious Side Effects

While Crizotinib has a targeted profile, patients must be closely monitored for a distinct set of potential side effects:

• Visual Disturbances: Very common, presenting as flashes of light, blurred vision, double vision, or floaters (usually mild and occurring early in treatment).
• Gastrointestinal Issues: Nausea, vomiting, diarrhea, and constipation are common but generally manageable with standard supportive medications and hydration.
• Hepatotoxicity: Can cause severe liver injury, presenting as elevated liver enzymes (ALT/AST).
• Pneumonitis/ILD: Severe, life-threatening inflammation of the lungs (Interstitial Lung Disease) can occur, requiring immediate medical attention if new respiratory symptoms develop.
• QT Prolongation: Can alter the electrical activity of the heart, requiring careful monitoring for irregular heart rhythms or dizziness.
• Edema: Swelling in the hands, feet, or legs due to fluid retention.
• Bradycardia: A slower-than-normal heart rate.

Drug Interactions

Crizotinib is primarily metabolized by the liver enzyme CYP3A4 and is also a moderate inhibitor of it. Certain substances can dangerously alter its levels:

• Strong CYP3A Inhibitors: (e.g., ketoconazole, clarithromycin, grapefruit juice)—these can drastically increase Crizotinib levels in the body, sharply raising the risk of severe toxicity.
• Strong CYP3A Inducers: (e.g., rifampin, phenytoin, St. John’s Wort)—these can drop drug levels significantly, making the treatment much less effective.
• QT-Prolonging Drugs: Concurrent use with other medications that prolong the QT interval requires extreme caution.

Pregnancy and Breastfeeding

• Embryo-Fetal Toxicity: Crizotinib can cause severe fetal harm or pregnancy loss. Highly effective contraception must be utilized by females of reproductive potential during treatment and for at least 4 months after the final dose. Male patients with female partners of reproductive potential must use condoms during treatment and for 3 months after the final dose.
• Breastfeeding: Due to the risk of serious adverse reactions in nursing infants, breastfeeding should be completely discontinued during Crizotinib therapy and for 45 days after the last dose.

Monitoring During Treatment

Your oncology care team will mandate regular assessments to ensure clinical safety:

• Liver Function Tests (LFTs): Monitored every two weeks for the first two months of treatment, and monthly thereafter, to check for drug-induced liver injury.
• Electrocardiograms (ECGs) & Electrolytes: Periodic heart checks to monitor the QT interval, along with blood tests for potassium and magnesium levels.
• Pulmonary Evaluation: Immediate investigation of any new or worsening respiratory symptoms (cough, shortness of breath, fever).
• Visual Assessment: Periodic eye exams or evaluation if visual changes persist or disrupt daily activities.

Generic Crizotinib

Generic versions of Crizotinib are manufactured globally under rigorous international bioequivalence standards:

• Cost-Effectiveness: Offers a drastically more affordable, budget-friendly option compared to the original brand-name drug (Xalkori).
• Therapeutic Equivalence: Contains the exact same active pharmaceutical ingredient, delivering identical clinical efficacy, safety profiles, and molecular mechanisms.
• Global Access: Expands international availability, ensuring that lung cancer patients worldwide can access life-prolonging precision oncology treatments.

Frequently Asked Questions (FAQs)

Is Crizotinib considered a traditional chemotherapy?

No. Crizotinib is a targeted tyrosine kinase inhibitor (TKI). It specifically blocks the abnormal ALK and ROS1 proteins driving the cancer, meaning it works entirely differently and has a completely distinct side-effect profile compared to conventional, cytotoxic chemotherapy.

Do I take Crizotinib in cycles?

No. Unlike standard chemotherapies that require rest weeks for your body to recover, Crizotinib is taken continuously every single day as long as it successfully controls the tumor growth and does not cause severe, unacceptable side effects.

Should I avoid any specific foods while taking Crizotinib?

Yes. You must strictly avoid grapefruit, grapefruit juice, and Seville oranges during your entire treatment course. These foods naturally block the liver enzymes responsible for breaking down Crizotinib, which can lead to dangerously high, toxic levels of the medication in your bloodstream.

Important Safety Information

This article is intended for educational purposes only and does not substitute for expert medical advice. Always consult a qualified oncologist or thoracic hematologist before initiating, adjusting, or stopping Crizotinib therapy. References

• U.S. Food and Drug Administration (FDA) Prescribing Information
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
• European Medicines Agency (EMA) Drug Information Portal
• American Society of Clinical Oncology (ASCO)

Contact Us

Are you searching for Generic Crizotinib, wholesale pricing structures, global availability, or export documentation?

Our expert team is fully equipped to guide you through trusted manufacturer selections, product availability, international licensing, and country-specific import regulations. Contact us today to learn more.

• Crizotinib